Table of Content

Open Access iconOpen Access

ARTICLE

Biochemical recurrence after robot-assisted extended pelvic lymphadenectomy for prostate cancer

Avinash Chenam1, Nora Ruel2, Sumanta Pal3, John Barlog1, Clayton Lau1, Timothy Wilson1, Bertram Yuh1

1 Department of Surgery, Division of Urology and Urologic Oncology, City of Hope National Medical Center, Duarte, California, USA
2 Department of Biostatistics, City of Hope National Medical Center, Duarte, California, USA
3 Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, California, USA
Address correspondence to Dr. Avinash Chenam, Division of Urology and Urologic Oncology, City of Hope National Medical Center, 1500 E. Duarte Rd, MOB L002H, Duarte, CA 91010 USA

Canadian Journal of Urology 2018, 25(3), 9340-9348.

Abstract

Introduction: Extended lymph node dissection (ELND) compared to limited lymph node dissection (LLND) at the time of prostatectomy improves staging and lymph node (LN) yield. The effect on biochemical recurrence (BCR) and survival is less well understood. We sought to evaluate the benefit of robotic ELND and LLND with respect to BCR.
Materials and methods: Between 2008-2012, 584 consecutive men with intermediate or high-risk clinically localized adenocarcinoma of the prostate underwent robotic-assisted radical prostatectomy (RARP) with concomitant LLND (n = 326) or ELND (n = 258). Survival estimates were made using the Kaplan-Meier method. Log-rank statistic was used for comparison of curves. BCR predictors were determined with multivariable Cox regression analysis. Chi-square and Wilcoxon rank-sum tests were used to compare discrete and continuous variables, respectively, across the two groups.
Results: Median follow-up for ELND and LLND patients was 46 and 54 months, respectively. ELND yielded more LNs (20 versus 6, p < 0.0001) and had higher node positivity (15.1% versus 3.4%, p < 0.0001). BCR-free survival (BCRFS) at 3 and 5 years for ELND and LLND was 85% and 75% (p = 0.01), and 76% and 67% (p = 0.10), respectively. In subgroup analysis, ELND was associated with higher 5-year BCRFS in node-negative patients (84% versus 68%, p = 0.0005) and in intermediate-risk patients (93% versus 80%, p = 0.0002). In multivariable analysis, ELND was a significant predictor of BCRFS in node-negative (HR = 0.50, p = 0.003) and intermediate-risk patients (HR = 0.54, p = 0.03).
Conclusions: ELND improves LN yield and detection of positive nodes. BCR analysis suggests a reduced risk of PSA failure for robotic ELND in intermediate-risk and node-negative patients.

Keywords

prostate cancer, extended lymph node dissection, biochemical recurrence

Cite This Article

APA Style
Chenam, A., Ruel, N., Pal, S., Barlog, J., Lau, C. et al. (2018). Biochemical recurrence after robot-assisted extended pelvic lymphadenectomy for prostate cancer. Canadian Journal of Urology, 25(3), 9340–9348.
Vancouver Style
Chenam A, Ruel N, Pal S, Barlog J, Lau C, Wilson T, et al. Biochemical recurrence after robot-assisted extended pelvic lymphadenectomy for prostate cancer. Can J Urology. 2018;25(3):9340–9348.
IEEE Style
A. Chenam et al., “Biochemical recurrence after robot-assisted extended pelvic lymphadenectomy for prostate cancer,” Can. J. Urology, vol. 25, no. 3, pp. 9340–9348, 2018.



cc Copyright © 2018 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 173

    View

  • 139

    Download

  • 0

    Like

Share Link